Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
KLOW GHK-Cu (50mg) / KPV (10mg) / BPC-157 (10mg) / TB500 (10mg) Description A four-component co-formulation supplied for controlled research environments
The synergistic effect of activating all three receptors simultaneously promotes significant weight loss and better metabolic control than other existing GLP-1 receptor agonists, such as semaglutide (Wegovy and Ozempic), liraglutide, dulaglutide, and dual-agonists like tirzepatide (Mounjaro and Zepbound)
These sympathomimetic drugs raise blood pressure and heart rate, and when combined with GLP-1 therapywhich can cause elevated heart rate as a side effectthey may create compounding cardiovascular stress
Immune modulation studies Animal and cell studies show BPC 157 may influence inflammation and oxidative stress
Starting both medications simultaneously makes it impossible to identify which medication is causing which side effects, makes dose titration dangerous because you cannot isolate responses, and maximizes the risk of overlapping side effects like nausea
Advertisement Kristin Louden: That they're not safe or that they're a shortcut
US$ 22.59
US$ 25.79
US$ 21.06
US$ 21.72
US$ 23.85
US$ 21.65
